GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (121 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: painperipheralskinnewcentral
  Phrases that lowered it: pharmacokineticmoderatevolunteersmaleexamination
• Design: crossover (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Phase: 1/2 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past termination rate: 6.7% (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports with a death: 12.3% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 29 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 4737 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 75.6% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports before start: 22127 (lowers risk) · Drug's FDA history
• Primary purpose: basic science (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 3 (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers NCT01011036 · started 2009 · scored riskier than 4% of active trials completed
• Exploring the Role of the GABAergic Modulation in Pain Transmission in Human NCT03375034 · started 2017 · scored riskier than 3% of active trials completed
• Effects of ICA-105665 Using the Intradermal Capsaicin and Ultraviolet B (UV-B) Models in Healthy Male Subjects NCT00962663 · started 2009 · scored riskier than 5% of active trials completed
• Experimental Biomarker Study for Pain Thresholds NCT02695745 · started 2011 · scored riskier than 2% of active trials completed
• Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers NCT01240148 · started 2010 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.